MC
REGN icon

Mathes Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Mathes Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,765
Closed -$648K – 135
2016
Q4 		$648K Sell
1,765
-1,370
-44% -$521K 0.36% 69
2016
Q3 		$1.26M Buy
3,135
+2,510
+402% +$1.01M 0.71% 44
2016
Q2 		$218K Hold
625
– – 0.13% 124
2016
Q1 		$226K Sell
625
-50
-7% -$20.6K 0.14% 117
2015
Q4 		$366K Hold
675
– – 0.21% 98
2015
Q3 		$314K Sell
675
-75
-10% -$40.3K 0.21% 100
2015
Q2 		$383K Sell
750
-25
-3% -$12.2K 0.2% 107
2015
Q1 		$350K Hold
775
– – 0.18% 125
2014
Q4 		$318K Buy
775
+100
+15% +$39.3K 0.17% 132
2014
Q3 		$243K Buy
+675
New +$226K 0.12% 149

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Mathes Company's REGN Position: Q1 2017 in Review

Mathes Company sold out of Regeneron Pharmaceuticals (REGN) in Q1 2017, closing a stake of 1,765 shares — an estimated $648K sold.

Mathes Company first reported a position in REGN in Q3 2014 and held it in 10 quarters. The position peaked at $1.26M in Q3 2016. 578 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

  • Mathes Company reported no remaining Regeneron Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Mathes Company sold 1,765 Regeneron Pharmaceuticals shares in Q1 2017, an estimated $648K.
  • Mathes Company first reported a position in Regeneron Pharmaceuticals in Q3 2014 and held it in 10 quarters.
  • Mathes Company's Regeneron Pharmaceuticals position peaked at $1.26M in Q3 2016.
  • 578 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on Mathes Company's 13F filing for Q1 2017, filed 24 Apr 2017.